

May 6, 2016

The Department of Corporate Services  
BSE Limited  
25<sup>th</sup> Floor, P. J. Towers  
Dalal Street  
Mumbai – 400 001.

Dear Sir,

**Subject : Outcome of Board Meeting**  
**Scrip Code : 533288**

A Meeting of the Board of Directors of Claris Lifesciences Limited ('the Company') was held today which commenced at 11.00 AM and concluded at 5:30 PM. The Board of Directors has considered, approved and taken on record the following:


1. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2016 along with Standalone and Consolidated Audit Report and Form A for the year ended March 31, 2016.
2. The Board of Directors of the Company has recommended a final dividend of Rs. 2 (Two) per Equity Share of Rs. 10/- each for the financial year ended March 31, 2016, subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Appointment of Mr. Amish Vyas, as an Additional Non-Executive and Non-Independent Director on the Board of the Company w.e.f May 6, 2016.


Kindly take the above information on your record.

Thanking You.

Yours faithfully,

**FOR CLARIS LIFESCIENCES LIMITED**

  
Chandrasingh Purohit  
**WHOLE TIME DIRECTOR & CFO**



**Encl: a/a**

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2016

(Rs.in Lacs except EPS and shares)

Particulars	Consolidated						Standalone					
	Quarter Ended			Year Ended	Year to Date	Period Ended	Quarter Ended			Year Ended	Year to Date	Period Ended
	31st Mar 2016 * Refer Note 8	31st Dec 2015	31st Mar 2015	31st Mar 2016	31st Mar 2015 * Refer Note 9	31st Mar 2015	31st Mar 2016 * Refer Note 8	31st Dec 2015	31st Mar 2015	31st Mar 2016	31st Mar 2015 * Refer Note 9	31st Mar 2015
	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited	Audited
				12 months	12 months	15 months				12 months	12 months	15 months
<b>PART I</b>												
<b>1. Income from Operations</b>												
a. Net Sales/Income from Operations ( Net of excise duty )	16,676.02	19,207.31	15,472.80	73,886.63	64,702.13	78,011.30	10,786.92	14,371.43	13,075.43	53,026.76	57,724.39	70,222.16
b. Other Operating Income	130.91	470.79	319.28	1,534.46	1,590.96	1,963.93	183.33	506.48	338.08	1,694.83	1,633.28	2,006.25
<b>Total Income from operations ( net )</b>	<b>16,806.93</b>	<b>19,678.10</b>	<b>15,792.08</b>	<b>75,421.09</b>	<b>66,293.09</b>	<b>79,975.23</b>	<b>10,970.25</b>	<b>14,877.91</b>	<b>13,413.51</b>	<b>54,721.59</b>	<b>59,357.67</b>	<b>72,228.41</b>
<b>2. Expenses</b>												
a. Cost of materials consumed	1,762.69	3,687.06	2,399.68	12,673.54	10,106.32	11,873.05	-	-	-	-	5,849.55	7,616.28
b. Purchase of stock-in- trade	3,157.39	3,035.77	4,844.13	14,804.03	19,548.47	26,274.43	9,818.18	13,117.80	12,259.03	48,631.96	31,130.05	37,267.94
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(690.76)	(72.05)	(610.33)	(270.46)	(1,720.86)	(2,691.47)	-	-	-	-	235.62	(427.69)
d. Employee benefits expense	2,827.67	2,076.50	2,942.30	8,674.64	8,198.51	9,257.02	471.11	350.65	1,664.02	1,858.26	5,706.63	6,661.50
e. Depreciation and amortisation expense	1,093.77	1,088.25	891.75	4,291.87	3,886.39	4,904.83	147.97	141.72	86.42	611.17	2,133.29	2,957.56
f. Other expenses	6,975.95	7,363.28	3,861.80	24,983.55	16,446.95	19,714.87	701.15	1,249.93	824.26	3,401.31	9,729.13	12,475.07
<b>Total Expenses</b>	<b>15,126.71</b>	<b>17,178.81</b>	<b>14,329.33</b>	<b>65,157.17</b>	<b>56,465.78</b>	<b>69,332.73</b>	<b>11,138.41</b>	<b>14,860.10</b>	<b>14,833.73</b>	<b>54,502.70</b>	<b>54,784.27</b>	<b>66,550.66</b>
<b>3. Profit / (Loss) from Operations before Other Income, finance costs and exceptional Items (1-2)</b>	<b>1,680.22</b>	<b>2,499.29</b>	<b>1,462.75</b>	<b>10,263.92</b>	<b>9,827.31</b>	<b>10,642.50</b>	<b>(168.16)</b>	<b>17.81</b>	<b>(1,420.22)</b>	<b>218.89</b>	<b>4,573.40</b>	<b>5,677.75</b>
4. Other Income	738.28	1,020.33	1,378.38	4,046.73	6,651.77	8,630.35	880.41	1,166.55	1,901.78	4,096.63	5,826.26	7,625.52
<b>5. Profit / (Loss) from ordinary activities before finance costs and exceptional Items (3+4)</b>	<b>2,418.50</b>	<b>3,519.62</b>	<b>2,841.13</b>	<b>14,310.65</b>	<b>16,479.08</b>	<b>19,272.85</b>	<b>712.25</b>	<b>1,184.36</b>	<b>481.56</b>	<b>4,315.52</b>	<b>10,399.66</b>	<b>13,303.27</b>
6. Finance Costs	1,090.03	1,037.10	1,045.89	4,277.04	3,952.03	4,826.04	199.41	74.69	58.49	386.94	2,233.08	3,104.40
<b>7. Profit / (Loss) from ordinary activities after finance costs but before exceptional Items (5-6)</b>	<b>1,328.47</b>	<b>2,482.52</b>	<b>1,795.24</b>	<b>10,033.61</b>	<b>12,527.05</b>	<b>14,446.81</b>	<b>512.84</b>	<b>1,109.67</b>	<b>423.07</b>	<b>3,928.58</b>	<b>8,166.58</b>	<b>10,198.87</b>
8. Exceptional Items [ Income / ( Expense ) ] ( Refer Note 5 )	-	-	-	-	-	-	-	-	-	-	523.03	523.03
<b>9. Profit / (Loss) from Ordinary Activities before tax (7+8 )</b>	<b>1,328.47</b>	<b>2,482.52</b>	<b>1,795.24</b>	<b>10,033.61</b>	<b>12,527.05</b>	<b>14,446.81</b>	<b>512.84</b>	<b>1,109.67</b>	<b>423.07</b>	<b>3,928.58</b>	<b>8,689.61</b>	<b>10,721.90</b>
10. Tax Expense	635.20	892.68	545.09	2,842.53	(1,598.86)	(1,220.36)	192.33	306.38	38.65	786.26	(3,522.25)	(3,147.06)
<b>11. Net Profit / (Loss) from Ordinary Activities after tax (9-10)</b>	<b>693.27</b>	<b>1,589.84</b>	<b>1,250.15</b>	<b>7,191.08</b>	<b>14,125.91</b>	<b>15,667.17</b>	<b>320.51</b>	<b>803.29</b>	<b>384.42</b>	<b>3,142.32</b>	<b>12,211.86</b>	<b>13,868.96</b>
12. Extraordinary Item (Refer Note 6)	-	-	-	3,783.19	-	-	-	-	-	3,783.19	-	-
<b>13. Net Profit / (Loss) for the period (11-12)</b>	<b>693.27</b>	<b>1,589.84</b>	<b>1,250.15</b>	<b>3,407.89</b>	<b>14,125.91</b>	<b>15,667.17</b>	<b>320.51</b>	<b>803.29</b>	<b>384.42</b>	<b>(640.87)</b>	<b>12,211.86</b>	<b>13,868.96</b>
14. Share in Profit/(Loss) from Associate (Refer Note 7)	(336.74)	(8,477.33)	(206.02)	(9,212.10)	(512.30)	(719.18)	-	-	-	-	-	-
15. Minority interest	-	-	-	-	-	-	-	-	-	-	-	-
<b>16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)</b>	<b>356.53</b>	<b>(6,887.49)</b>	<b>1,044.13</b>	<b>(5,804.21)</b>	<b>13,613.61</b>	<b>14,947.99</b>	<b>320.51</b>	<b>803.29</b>	<b>384.42</b>	<b>(640.87)</b>	<b>12,211.86</b>	<b>13,868.96</b>
17. Paid-up equity share capital (Face Value - Rs. 10/- Per Share)	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78
18. Reserve excluding Revaluation Reserves (As per Balance Sheet of previous accounting year)	-	-	-	1,19,773.87	-	1,26,214.10	-	-	-	78,311.45	-	80,300.36
<b>19. Basic and Diluted Earnings Per Share (EPS)</b>												
- before extraordinary items ( of Rs. 10/- each ) (Not Annualised)	0.65	(12.62)	1.91	(3.70)	24.21	25.89	0.59	1.47	0.70	5.76	21.71	24.02
- after extraordinary items ( of Rs. 10/- each ) (Not Annualised)	0.65	(12.62)	1.91	(10.64)	24.21	25.89	0.59	1.47	0.70	(1.17)	21.71	24.02
See accompanying note to the financial results												





1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th May, 2016.

2 Consequent to the applicability of Companies Act, 2013 (The Act) to accounting periods commencing from 1st April 2015 to the Company, the Company has charged depreciation on various fixed assets as per the useful lives specified in part C of Schedule II of the Companies Act 2013. The carrying value, net-off residual value of the fixed assets whose useful lives are already exhausted on 31st March 2015 have been adjusted to retained earnings.

3 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.


4 During the financial period of fifteen months ended on 31st March, 2015, on receipt of necessary approvals from Board of Directors and Shareholders of the Company at their meetings held on 4th July, 2014 and 3rd September, 2014 respectively in respect of transfer of its Injectables Business on Slump Sale basis, the Company has transferred its Injectables Business to its wholly owned subsidiary namely Claris Injectables Limited (formerly known as Claris Lifesciences International Limited) on 31st October, 2014. The business transfer involved transfer of relevant assets and liabilities as stated in the Business Transfer Agreement of Injectables Business on a "slump sale basis" for an agreed cash consideration of Rs. 55,400 lacs. The Company has registered a profit of Rs 523.03 lacs on account of slump sale of Injectables Business.

(Rs in Lacs)

The Key financial numbers pertaining to the discontinued business									(Rs in Lacs)
Particulars	Consolidated				Standalone				
	Quarter Ended			Period ended	Quarter Ended			*Period ended	
	31st Mar 2016	31st Dec 2015	31st Mar 2015	31st Mar 2015	31st Mar 2016	31st Dec 2015	31st Mar 2015	31st Mar 2015	
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited	
				15 months				15 months	
Revenue	-	-	-	-	-	-	-	35,254.24	
Expenditure	-	-	-	-	-	-	-	29,591.40	
PBT	-	-	-	-	-	-	-	5,662.84	
PAT	-	-	-	-	-	-	-	4,010.53	
						-			
Particulars	Consolidated period ended				Standalone period ended				
	31st Oct 2014				31st Oct 2014				
	Unaudited				Unaudited				
Total Assets									1,02,163.15
Total Liabilities									47,286.18

\* The Company Operates in single segment and in the view of the common expenditure - employee, marketing expenses, logistic & distribution arrangements and general corporate overheads are not separately identifiable for the identified products. However, the figures of Profit Before Tax and Profit After Tax for the period 1st January, 2014 to 31st March, 2015 have been apportioned and calculated on best estimated basis. Since the Business has been transferred to wholly owned subsidiary, there is no impact on consolidated financial results of the Company due to transfer of Injectable Business ( i.e. Discontinued Operation).

- |    |   |
|----|---|
| 5  | In the audited standalone financial result for the fifteen months period ended on 31st March, 2015, the exceptional item stated therein of Rs. 523.03 lacs pertains to profit on transfer of Injectables Business to Claris Injectables Limited, the wholly owned subsidiary of the Company, on a slump sale basis as stated in note 4 above.   |
| 6  | Extraordinary item stated in item no 12 during the year ended on 31st March, 2016 represents expenses of Rs 3,783.19 lacs, incurred relating to legal, professional, travelling and consultancy etc. on account of various Strategic and Management initiatives of which majority of expenses are of prior year / quarter.  |
| 7  | Share in loss from Associate Company i.e. Claris Otsuka Private Limited for the year ended on 31st March 2016 amounting to Rs. 9,212.10 lacs as stated in item no. 14 is on account of impairment of Intangible Assets carried out by Claris Otsuka Private Limited and its business operations.  |
| 8  | Figures for the quarter ended on 31st March 2016 are balancing figures between audited figures for the financial year ended on 31st March 2016 and nine months unaudited figures ended on 31st December 2015.   |
| 9  | During the fifteen months ended 31st March, 2015, the Company had changed its financial year from January-December to April-March. In view of this, the previous financial year was for a period of fifteen months i.e. 1st January 2014 to 31st March 2015. Accordingly in these results for the quarter and twelve months period ended 31st March, 2015 is disclosed as corresponding quarter and corresponding twelve months of the previous period respectively. The figures for the corresponding quarter / twelve months ended 31st March, 2015 are the balancing figures between audited published figures in respect of the fifteen months ended 31st March, 2015 and (i) unaudited published figures for the 12 months period ended 31st December, 2014 and (ii) unaudited published figures for the three months period ended on 31st March, 2014 respectively. |
| 10 | The Board of Directors have recommended final dividend of Rs 2 per Equity Share of Rs 10 each for the financial year ended on 31st March, 2016, subject to the approval of Shareholders at the ensuing Annual General Meeting.  |



Particulars	Consolidated		Standalone	
	As at	As at	As at	As at
	31st Mar 2016	31st Mar 2015	31st Mar 2016	31st Mar 2015
	Audited	Audited	Audited	Audited
<b>A. EQUITY AND LIABILITIES</b>				
<b>1. Shareholders' Funds:</b>				
Share Capital	5,456.78	5,456.78	5,456.78	5,456.78
Reserves and Surplus	1,19,773.87	1,26,214.10	78,311.45	80,300.36
<b>Sub-total - Shareholders' funds</b>	<b>1,25,230.65</b>	<b>1,31,670.88</b>	<b>83,768.23</b>	<b>85,757.14</b>
<b>2. Minority Interest</b>	-	-	-	-
<b>3. Non - current liabilities</b>				
Long-term borrowings	35,509.03	27,342.96	1,189.36	1,431.68
Deferred tax liabilities (net)	2,948.94	967.13	233.71	272.57
Other long-term liabilities	-	-	-	-
Long-term provisions	1,411.71	1,000.75	376.98	250.61
<b>Sub-total - Non-current liabilities</b>	<b>39,869.68</b>	<b>29,310.84</b>	<b>1,800.05</b>	<b>1,954.86</b>
<b>4. Current liabilities</b>				
Short-term borrowings	17,099.92	18,387.91	-	2,265.76
Trade payables	14,556.11	12,678.52	12,024.78	9,564.33
Other current liabilities	12,028.29	25,328.11	10,874.64	26,876.54
Short-term provisions	2,258.60	1,001.18	1,648.70	460.84
<b>Sub-total - Current liabilities</b>	<b>45,942.92</b>	<b>57,395.72</b>	<b>24,548.12</b>	<b>39,167.47</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>2,11,043.25</b>	<b>2,18,377.44</b>	<b>1,10,116.40</b>	<b>1,26,879.47</b>
<b>B. ASSETS</b>				
<b>1. Non - current assets</b>				
Goodwill on Consolidation	3.20	3.20	-	-
Fixed assets	1,11,465.93	1,07,708.39	6,223.16	4,010.25
Non - current investments	11,800.79	20,230.89	51,412.18	1,926.96
Long-term loans and advances	5,559.02	1,531.23	1,746.15	887.73
Other non-current assets	385.81	507.87	-	-
<b>Sub-total - Non-current assets</b>	<b>1,29,214.75</b>	<b>1,29,981.58</b>	<b>59,381.49</b>	<b>6,824.94</b>
<b>2. Current assets</b>				
Current investments	17,702.56	33,161.25	17,702.56	33,161.25
Inventories	9,444.72	9,374.98	-	-
Trade receivables	22,673.42	22,914.95	12,742.69	15,184.98
Cash and cash equivalents	18,619.06	8,256.57	4,526.11	4,424.12
Short-term loans and advances	11,716.43	13,277.27	8,756.95	11,070.17
Other current assets	1,672.31	1,410.84	7,006.60	56,214.01
<b>Sub-total - Current assets</b>	<b>81,828.50</b>	<b>88,395.86</b>	<b>50,734.91</b>	<b>1,20,054.53</b>
<b>TOTAL - ASSETS</b>	<b>2,11,043.25</b>	<b>2,18,377.44</b>	<b>1,10,116.40</b>	<b>1,26,879.47</b>

12 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

Place: Ahmedabad  
Date: 6th May, 2016

For Claris Lifesciences Limited

  
 Chandrasingh Purohit  
 Whole-time Director & CFO




**SHAH & SHAH ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

702, ANIKET,  
Nr. MUNICIPAL MARKET,  
C.G. ROAD, NAVRANGPURA,  
AHMEDABAD - 380 009.  
PHONE: 26465433  
FAX : 079 - 26406983 Email:  
ca@shahandshah.co.in

**Independent Auditor's report on standalone results of Claris Lifesciences Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**

TO  
THE BOARD OF DIRECTORS OF  
**CLARIS LIFESCIENCES LIMITED**

We have audited the accompanying Statement of Standalone Financial Results ("the statement") of **CLARIS LIFESCIENCES LIMITED, AHMEDABAD** ("the company") for the quarter and year ended on 31<sup>st</sup> March, 2016, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015). This statement has been prepared on the basis of the related annual standalone financial statements, which is the responsibility of the company's management and approved by the Board of Directors. Our responsibility is to express an opinion on the statement, based on our audit of related annual financial statements of the company, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting amount disclosed in the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion and to the best of our information and according to the explanations given to us, this statement:

- i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net loss and other financial information of the company for the year ended on 31<sup>st</sup> March, 2016.

The statement includes the results for the Quarter ended on 31<sup>st</sup> March, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year-to-date figures up to third quarter ended on 31<sup>st</sup> December, 2015 which were subject to limited review by us.

For **SHAH & SHAH ASSOCIATES**  
Chartered Accountants  
**FRN:113742W**



Place : Ahmedabad.  
Date : 06.05.2016

**PARTNER**  
Name: **SUNIL K. DAVE**  
Membership Number: 047236

**SHAH & SHAH ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

702, **ANIKET**,  
Nr. MUNICIPAL MARKET,  
C.G. ROAD, NAVRANGPURA,  
AHMEDABAD - 380 009.  
PHONE: 26465433  
FAX : 079 - 2640698  
Email: a@shahandshah.co.in

**Independent Auditor's report on Consolidated Results of Claris Lifesciences Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

TO  
THE BOARD OF DIRECTORS OF  
**CLARIS LIFESCIENCES LIMITED**

We have audited the accompanying Statement of Consolidated Financial Results of **CLARIS LIFESCIENCES LIMITED** and its subsidiaries (the Company and its subsidiaries constitute "the Group") and the company's share of the profit / (loss) of its associate for the quarter and year ended on 31st March, 2016 (the "Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement has been prepared on the basis of the related annual consolidated financial statements, which is the responsibility of the company's management and approved by the Board of Directors. Our responsibility is to express an opinion on the statement, based on our audit of related annual consolidated financial statements of the company, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting amount disclosed in the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

We did not audit the financial statements of nineteen subsidiaries and an associate included in the consolidated financial results, whose financial statements reflect, total assets of Rs. 1,49,992.52 Lacs as at 31<sup>st</sup> March, 2016, total revenues of Rs. 17,512.42 Lacs and Rs. 47,647.45 Lacs for the quarter and year ended on 31st March, 2016 respectively, and total profit after tax of Rs. 2604.89 Lacs and loss after tax of Rs. 18,038.99 Lacs for the quarter and year ended on 31st March, 2016 respectively, as considered in the consolidated financial results. These interim/final financial statements of nineteen subsidiaries have been audited/reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors. Further, our report on the Statement, in so far as it relates on share of loss of an associate is based solely on the financial statements as submitted by the management of the associate company to the company.





**SHAH & SHAH ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

702, **ANIKET**,  
Nr. MUNICIPAL MARKET,  
C.G. ROAD, NAVRANGPURA,  
AHMEDABAD - 380 009.  
PHONE: 26465433  
FAX : 079 - 2640698  
Email: a@shahandshah.co.in

In our opinion and to the best of information and according to the explanations given to us, this statement;

i) includes the results of the entities given below:

(i) PT. Claris Lifesciences Indonesia, (ii) Claris Lifesciences Colombia Ltda., (iii) Catalys Venture Cap Limited, (iv) Claris Lifesciences Venezuela C. A. (v) Claris Lifesciences Inc. (vi) Claris Lifesciences (UK) Limited (vii) Claris Lifesciences & Cia. Chile Limitada, (viii) Claris Lifesciences (Aust) Pty Limited (ix) Claris Lifesciences de Mexico S.A. de C.V. (x) Claris Produtos Farmaceuticos do Brasil Ltda. (xi) Claris Lifesciences Philippines, INC. (xii) Claris Infrastructure Limited, (xiii) Claris SteriOne, (xiv) Claris Pharmaservices, (xv) iCubix Infotech Limited, (xvi) Claris Injectibles Limited, (xvii) Ogen Nutrition Limited and (xviii) Claris Middle East FZ-LLC, Dubai. (xix) Elda International DMCC, (xx) Claris Capital Limited. (xxi) Claris Otsuka Private Limited (Associate Company).

ii) has been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

iii) gives a true and fair view of the consolidated net profit and other financial information for the year ended on 31st March, 2016.

The statement includes the results for the Quarter ended on 31st March, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year-to-date figures up to third quarter ended on 31st December, 2015 which were subject to limited review by us.

For **SHAH & SHAH ASSOCIATES**

Chartered Accountants

**FRN:113742W**



**PARTNER**

Name: SUNIL K. DAVE

Membership Number: 047236

Place : Ahmedabad.

Date : 06.05.2016

**FORM A**


**Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015**

- |   |  |   |
|---|--|---|
| 1 | Name of the Company                            | : Claris Lifesciences Limited   |
| 2 | Annual financial statements for the year ended | : Standalone Financial Statement<br>for the year ended on March 31,<br>2016 |
| 3 | Type of Audit Observation                      | : Un Modified   |
| 4 | Frequency of observation                       | : Not Applicable  |
| 5 | To be signed by -                              |   |


**Vice-chairman & Managing Director**

  
Arjun Handa

**Whole-time Director & CFO**

  
Chandrasingh S. Purohit

**Audit Committee Chairman**

  
Anup P. Shah

**Auditor of the Company**

**Refer Our Audit Report dated  
May 6 , 2016 on the standalone  
financial statements of the  
Company**

**For, Shah & Shah Associates  
Chartered Accountants  
FRN : 113742W**

  
Suni K. Dave  
**Partner**  
Membership No 047236




FORM A


Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015

- |   |  |   |
|---|--|---|
| 1 | Name of the Company                            | : Claris Lifesciences Limited   |
| 2 | Annual financial statements for the year ended | : Consolidated Financial Statement<br>for the year ended on March 31,<br>2016 |
| 3 | Type of Audit Observation                      | : Un Modified   |
| 4 | Frequency of observation                       | : Not Applicable  |
| 5 | To be signed by -                              |   |


Vice-chairman & Managing Director

  
Arjun Handa

Whole-time Director & CFO

  
Chandrasingh S. Purohit

Audit Committee Chairman

  
Anup P. Shah

Auditor of the Company

Refer Our Audit Report dated  
May 6 , 2016 on the  
Consolidated Financial  
Statements of the Company

For, Shah & Shah Associates  
Chartered Accountants  
FRN : 113742W

  
Suni K. Dave  
Partner  
Membership No 047236